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Abstract
Women are associated with longer electrocardiographic QT intervals and increased proarrhythmic risks of QT-prolonging drugs. The purpose of
this study was to characterize the differences in cardiac electrophysiology between moxifloxacin and levofloxacin in men and women and to assess
the balance of inward and outward currents through the analysis of QT subintervals. Data from 2 TQT studies were used to investigate the impact
of moxifloxacin (400 mg) and levofloxacin (1000 and 1500 mg) on QT subintervals using algorithms for measurement of J-Tpeak and Tpeak-Tend
intervals. Concentration-effect analyses were performed to establish potential relationships between the ECG effects and the concentrations of the 2
fluoroquinolones.Moxifloxacin was shown to be a more potent prolonger of QT interval corrected by Fredericia (QTcF) and had a pronounced effect
on J-Tpeakc. Levofloxacin had little effect on J-Tpeakc. For moxifloxacin, the concentration-effect modeling showed a greater effect for women on QTcF
and J-Tpeakc,whereas for levofloxacin the inverse was true:women had smaller QTcF and J-Tpeakc effects. The different patterns in repolarization after
administration of both drugs suggested a sex difference,which may be related to the combined IKs and IKr inhibitory properties of moxifloxacin versus
IKr suppression only of levofloxacin. The equipotent inhibition of IKs and IKr appears to affect women more than men. Sex hormones are known to
influence cardiac ion channel expression and differences in QT duration. Differences in IKr and IKs balances, influenced by sex hormones, may explain
the results. These results support the impact of sex differences on the cardiac safety assessment of drugs.
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Distinct ion channels contribute to defining the mor-
phology and duration of the cardiac action potential.
To characterize drug proarrhythmic properties, it is of
interest to explore which ionic currents play a signif-
icant role. It has been demonstrated that the balance
of inward and outward currents can be detected in
the ECG by analyzing the QT subintervals. IKr or
hERG-encoded potassium channel blockade prolongs
both early repolarization (J-Tpeak) and late repolariza-
tion (Tpeak-Tend), whereas multichannel blockers may
shorten or have no effect on J-Tpeak,1 depending on
which channels are blocked and how potently as well
as whether these channels facilitate depolarization or
repolarization currents.
It is widely accepted that women are more prone
to developing drug-induced arrhythmia.2–4 Vicente et
al reported sex- and age-specific measurements for
all the QT subintervals in healthy subjects in 2014,
demonstrating men to have a shorter rate-corrected
QT interval (QTc) than women. Despite longer depo-
larization (QRS) and late repolarization (Tpeak-Tend)
phases, men have reduced early repolarization (J-Tpeak)
when compared with women, which summates to an
overall shorter QTc.5 This difference develops during
puberty and diminishes with age. It is thought that
sex hormones may play a role; simulated testosterone
studies have shown that the male sex hormone affects
both ICaL and IKs, contributing to sex differences in
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early repolarization.4,5 Additionally, it has been sug-
gested that endogenous testosterone (IKr and IKs up-
regulator) and progesterone (IKs upregulator) shorten
the cardiac action potential. Endogenous estrogen (IKr
and IKs downregulator) is thought to lengthen the
cardiac action potential.6 Studies of menopausal hor-
mone therapy in the form of estrogen-alone therapy
and estrogen plus progesterone therapy have suggested
a counterbalancing effect of exogenous estrogen and
progesterone on the QT. Specifically, estrogen-alone
therapy lengthens the QT, whereas estrogen plus pro-
gesterone therapy has no effect.7
Fluoroquinolones are one of the most commonly
prescribed class of antibiotics worldwide.8
Prolongation of the QT interval is an adverse effect
associated with the use of fluoroquinolones and has
been the basis for their use as positive controls for
thorough QT studies.9,10 Fluoroquinolones prolong
the QT interval by blocking voltage-gated potassium
channels, especially the “rapid” component of the
delayed rectifier current IKr, expressed by hERG
(the human ether-a`-go-go-related gene). However,
the degree of QT interval prolongation appears to
differ among fluoroquinolones. The overall risk of
torsades de pointes (TdP) is small with the use of
fluoroquinolones but has been documented in clinical
studies and case reports.11,12 Moxifloxacin has been
used in the majority of TQT studies, and it is known
to influence ventricular repolarization by inhibiting the
IKr channel.13,14 Oral moxifloxacin leads to an average
QTc prolongation of 10-14 ms at a dose of 400 mg.15–17
Levofloxacin, another fluoroquinolone, has also been
shown to block hERG channels13,18 and cause changes
in the QTc interval.19,20 The effect of supratherapeutic
oral doses of levofloxacin on the QTc intervals of 4.73
and 7.12 ms was shown for 1000-mg and 1500-mg
doses, respectively.19
Recently, Matsukura et al21 indicated that mox-
ifloxacin significantly prolonged both J-Tpeakc and
Tpeak-Tend. Additionally, women were found to be more
sensitive to overall QTc by Fredericia (QTcF) prolonga-
tion and (more specifically) to J-Tpeak prolongation in a
concentration-effect model analysis.
The purpose of the present study was to use com-
bined data from 2 TQT studies comparing QTcF
changes after supratherapeutic doses of levofloxacin
(which is thought to primarily block hERG channels)
and therapeutic doses of moxifloxacin (which has been
shown to block both hERG and KvLQT1/mink).1,14
The 2 studies were performed in the same year at the
same clinical research unit using identical procedures
for clinical conduct and ECG analysis. Both studies
were balanced for sex, and the analyses performed in
the moxifloxacin arm of each study were identical.
This investigation characterizes the differences in early
repolarization (J-Tpeak) and late repolarization (Tpeak-
Tend) between moxifloxacin and levofloxacin and fur-
ther defines observed sex differences in QTcF and its
subintervals.
Materials and Methods
Study Design
Study 1 (EudraCT: 2006-006376-38) was approved by
the local ethics committee (Covance Clinical Research
Unit, Independent Ethics Committee, Leeds, UK) and
the Medicines and Healthcare Products Regulatory
Authority and was conducted in accordance withGood
Clinical Practice and the Declaration of Helsinki. This
was a randomized, placebo-controlled, double-blinded,
double-dummy, single-center, 4 × 4 crossover study. It
consisted of 64 healthy, white volunteers (34 male and
30 female) who all provided written, informed consent
before any study-specific procedures.
The study evaluated the effects of 2 single suprather-
apeutic oral doses of levofloxacin (1000 mg and
1500 mg Tavanic; Laboratoire Aventis, Groupe Sanofi-
Aventis, Paris, France) and 1 single standard oral
dose of moxifloxacin (400 mg Izilox; Bayer Pharma
SAS, Puteaux, France) on the QTc intervals of healthy
volunteers compared with a placebo group.14 Each of
the 4 periods consisted of 2 days: 1 placebo baseline
day and 1 treatment day. These were separated by a
2-day washout period. The study design, ECG, and
pharmacokinetic assessments were fully detailed by
Taubel et al.19
Study 2 (EudraCT: 2006-002504-34) was approved
by the local ethics committee (North London REC
3, Harrow, UK), and the Medicines and Health-
care Products Regulatory Authority and was con-
ducted in accordance with Good Clinical Practice
and the Declaration of Helsinki. This was a random-
ized, placebo-controlled, positive-controlled, double-
blinded, double-dummy, single-center, 3 × 3 crossover
study. It consisted of 96 healthy, white volunteers (47
male and 49 female) who all provided written, informed
consent before any study-specific procedures.
The study evaluated the effects of supratherapeutic
repeated dosing of 4 g of once-daily strontium ranelate
(Protelos; Les Laboratoires Servier, Neuilly-sur-Seine,
France) for 15 days on the QTc interval of healthy vol-
unteers. Eligible subjects were randomized to strontium
ranelate, placebo, or moxifloxacin for the 3 treatment
periods. Each treatment period consisted of 16 days:
day 1 was the placebo baseline day at the unit; days
2-15 were out of the unit, and participants were on
placebo or strontium ranelate. The final day (day 16)
was spent at the unit, and the volunteers had either
placebo, strontium ranelate, or moxifloxacin (Izilox;
Bayer Pharma SAS, Puteaux, France). The treatment
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periods were separated by 28-day washout periods. The
methods used for ECG and pharmacokinetic assess-
ments are described elsewhere.22
ECG Recording and Data Processing
Twelve-lead ECGs were recorded as described by
Taubel et al.19,22 Data were processed by the Depart-
ment of Health Science and Technology of the Fac-
ulty of Medicine, University of Aalborg (Denmark).
They used the commercially available GE Healthcare
Marquette 12SL ECG analysis program and the US
Food and Drug Administration 510(k)-cleared GE
research packageQTGuardPlus.18,19 This software uses
the simultaneous vector magnitude of all 12 leads to
determine the onset and offset of the QRS complex as
well as the offset of the T wave. The vector magnitude
is a global single-lead representation of all 12 leads that
did not display a biphasic (+/– or –/+) T wave. In cases
with clear biphasic T waves in some of the leads, the
vector magnitude representation may have displayed 2
obvious positive peaks in the T wave. In these cases the
algorithm used the second peak of the T wave, the peak
closer to the end. The end of the T wave is determined
by the method of small windows.23,24
J-Tpeak was heart-rate corrected using J-TpeakcJ.25 At
resting heart rates Tpeak-Tend exhibits minimal heart-
rate dependency, and, therefore, correction was not
made.26
Statistical Analyses
Themoxifloxacin ECGand pharmacokinetic data from
studies 1 and 2 were combined. In total, 9315 ECGs
were used in the moxifloxacin analysis: 1364 and 1741
triplicate ECGs from 61 subjects in the moxifloxacin
treatment in study 1 and 72 subjects in the moxifloxacin
treatment in study 2, respectively. To ensure consistency
across the 2 studies, the values from the first day of
each period (placebo baseline day) at the time points
0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, and 24 hours (common
time points to the 2 studies) were averaged by subject
and period to calculate baseline. The levofloxacin data
were taken from study 1 only: 1385 triplicate ECGs
from 62 subjects in the 1000-mg levofloxacin treatment
and 1361 triplicate ECGs from 62 subjects in the
1500-mg levofloxacin treatment, resulting in a total of
8238 ECGs that were analyzed. The baseline-corrected
variables (QTcF, J-TpeakCj, and Tpeak-Tend) were
obtained by subtracting the baseline from the postdose
value, by subject and time point within each period. The
baseline and placebo-corrected variables were obtained
by subtracting the baseline-corrected variable of the
placebo period from the baseline-corrected variable of
the drug administration period. All time points were
used for these variables: 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4,
Table 1. Subject Demographics
Study 1 Study 2
Number of subjects enrolled 64 96
Age (y) 29 ± 7 27.7 ± 7.5
Sex (n)
Male 34 (53%) 47 (49%)
Female 30 (47%) 49 (51%)
BMI (kg m−2) 24.1 ± 2.3 24.1 ± 2.8
Race (n)
White 64 (100%) 96 (100%)
BMI indicates body mass index.
8, 12, and 24 hours for study 1 and 0, 0.5, 1, 1.5, 2, 3, 4,
5, 6, 8, 12, and 24 hours for study 2.
Mixed Models. The analysis follows the general sta-
tistical principles described by Garnett et al.27 To as-
certain whether the ECG markers differed between sex
groups through the concentration profile, the analysis
involved a mixed model for each outcome variable
(QTcF, J-TpeakcJ, and Tpeak-Tend), with sex
and the interaction between concentration and sex as
fixed effects. The random term included intercepts and
concentration by subject.
The mixed models were fitted in SAS Enterprise
Guide version: 7.1 (7.15 HF3 [7.100.5.6132]) with SAS
version 9.4 (9.04.01M5P09132017) using the Restricted
Maximum Likelihood method. For the degrees of free-
dom, the Kenward-Roger approach was used. All 2-
sided confidence intervals are calculated using α = 0.1.
An unstructured covariancematrix was assumed for the
random effects.
Results
Subject Demographics and Disposition
Subject demographics are presented by descriptive
statistics in Table 1.
Three subjects from study 1 were withdrawn, 2
because of adverse events following treatment with
moxifloxacin 400 mg (1 subject suffered from sustained
supraventricular tachycardia, and the second suffered
from anxiety). No serious or severe adverse events were
observed.14
Twenty-six subjects were withdrawn in study 2. This
was because of the very long duration of the trial due
to a multiple-dose crossover design. One withdrew due
to an adverse event after receiving moxifloxacin 400
mg (the subject experienced flu-like symptoms and was
found pyrexial). Twenty-two participants were with-
drawn for nonmedical reasons, and 3 were withdrawn
due to noncompliancewith protocol requirements (test-
ing positive for drugs of abuse in subsequent treatment
periods). There were no serious or severe adverse events
in this study.
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In the descriptive and statistical analysis described
here, data from 61 subjects (28 women and 33men) who
received 400mgmoxifloxacin and data from 62 subjects
who received levofloxacin (29 female and 33 male)
have been included from study 1. From study 2, data
from 72 subjects (35 female and 37 male) who received
400 mg moxifloxacin were included. The time course
analysis data for moxifloxacin by study are presented in
Supplemental Tables S1-S3.Overall, the point estimates
were very similar between studies.
Time Course Analyses
The effects of moxifloxacin and levofloxacin on the
QTcF, J-TpeakcJ, and Tpeak-Tend are sum-
marized in Figure 1. Generally, the effects on women
were greater than those on men. This is unsurprising
given the higher plasma concentrations due to demo-
graphic differences between sexes.
QTcF. The largest QTcF with moxifloxacin
was registered at 3.5 hours for both men (12.43 ms,
90%CI 10.56-14.31) and women (16.80 ms, 90%CI
13.88-19.72). Similarly, 1000 mg of levofloxacin pro-
duced the largestQTcF at 2 hours for men (6.86ms,
90%CI 5.11-8.62) and at 2.5 hours for women (7.51 ms,
90%CI 5.70-9.33). Following a 1500-mg dose, men
showed the greatest QTcF at 3 hours (9.91 ms,
90%CI 7.83-12.00), whereas women still showed the
biggest difference at 3.5 hours (10.28 ms, 90%CI 8.16-
12.40).
J-TpeakcJ. Whenmoxifloxacin is administered, the
highest J-TpeakcJ value observed in women was at
2 hours (10.86 ms, 90%CI 8.71-13.01). Men showed a
smaller effect, and their highest value was displayed at
1 hour (7.21 ms, 90%CI 5.69-8.73).
When compared with moxifloxacin, the levofloxacin
effect on J-TpeakcJ was short-lived, particularly
in men, where values returned to baseline within 3-4
hours. In women, effects persisted for longer, returning
to baseline by 8 hours. Notably, at the 8 hours’ time
point, women still showed a greater prolongation of
J-TpeakcJ after a dose of moxifloxacin. The effects
of 1000 mg levofloxacin on J-TpeakcJ were highest
at 1.5 hours in women (3.86 ms, 90%CI 1.82-5.91) and
at 2 hours inmen (4.52ms, 90%CI 3.17-5.88). The 1500-
mg dose of levofloxacin led to an increase of 5.08 ms
(90%CI 3.29-6.87) at 1.5 hours in men and 4.43 ms
(90%CI 2.77-6.08) at 2 hours in women.
Tpeak-Tend. The highestTpeak-Tend values fol-
lowing administration of moxifloxacin were observed
at 3.5 hours in both men (5.31 ms, 90%CI 4.12-6.49)
and women (5.69 ms, 90%CI 3.89-7.50). The largest
values with 1000 mg levofloxacin were at 3.5 hours
Table 2. Summary of Intercepts and Slopes Obtained by
Concentration-Effect Modeling
Moxifloxacin
Slope (ms/[μg/mL]) Intercept (ms)
Estimate 90%CI Estimate 90%CI
QTcF Male 4.7030 4.0842 5.3217 1.9757 0.4349 3.5166
Female 4.9893 4.4475 5.5310 3.1651 1.5514 4.7788
J-TpeakcJ Male 3.3362 2.7835 3.8890 0.1106 –1.2909 1.5121
Female 3.5921 3.1102 4.0740 1.8607 0.3927 3.3287
Tpeak-Tend Male 1.2338 0.8640 1.6036 1.8283 0.9896 2.6671
Female 1.3462 1.0304 1.6620 1.1385 0.2619 2.0152
Levofloxacin
Slope (ms/[μg/mL]) Intercept (ms)
Estimate 90%CI Estimate 90%CI
QTcF Male 0.8636 0.7195 1.0076 –0.6135 –1.9374 0.7105
Female 0.7115 0.5723 0.8507 –0.4185 –1.8261 0.9892
J-TpeakcJ Male 0.3376 0.2205 0.4547 0.3337 –0.6236 1.2910
Female 0.2047 0.09395 0.3155 –0.1555 –1.1717 0.8608
Tpeak-Tend Male 0.3201 0.2376 0.4026 –0.7692 –1.5280 0.01044
Female 0.4446 0.3670 0.5222 –0.6903 –1.4965 0.1160
for men (2.05 ms, 90%CI 1.12-2.98) and at 3 hours
for women (4.42 ms, 90%CI 3.29-5.55). The 1500-mg
levofloxacin cohort showed the same pattern with a
maximum increase of 4.32 ms (90%CI 3.09-5.55) for
men at 3.5 hours and 7.02 ms (90%CI 5.37-8.68) at 3
hours for women. The curves forTpeak-Tend clearly
separate after both doses of levofloxacin and remain
elevated up to 4 hours.
Concentration-Effect Analysis
For each subject, the maximum concentration of
the analytes moxifloxacin and levofloxacin was mea-
sured and used for calculating the overall and by-sex
geometric means. The moxifloxacin geometric mean
peak concentration (Cmax) was 2.49 μg/mL (men 2.27;
women 2.75). The levofloxacin geometric mean Cmax
was 11.37 μg/mL for men and 13.97 μg/mL for women
(overall Cmax 12.54 μg/mL).
The relationships between moxifloxacin and lev-
ofloxacin plasma concentrations and their respective
predicted QTcF, J-TpeakcJ, and Tpeak-Tend
values are shown in Figure 2. The slopes and intercepts
for all parameters are summarized in Table 2.
Moxifloxacin
QTcF values increased with the concentration of
moxifloxacin for both men and women. Women had
almost consistently higher values for QTcF com-
pared with men across the concentration profile (Fig-
ure 2). The statistical model predictedQTcF values
at the overall Cmax of 14.6 ms (90%CI 13.41-15.77). At
their respective Cmax levels, theQTcF was 12.62 ms
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Figure 1. Time course of (A) QTcF, J-TpeakcJ, and Tpeak-Tend and (B) plasma concentration following administration of 400 mg
moxifloxacin and 1000 mg and 1500 mg levofloxacin. B, Vertical bars represent 2-sided 90%CIs of the mean. Te indicates Tend; Tp, Tpeak.
(90%CI 11.02-14.21) for men and 16.9 ms (90%CI
15.17-18.63) for women.
There was a positive relationship between mox-
ifloxacin plasma concentrations and the predicted
J-TpeakcJ (Figure 2 and Table 2). The estimated
J-TpeakcJ at Cmax for men was 7.66ms (90%CI 6.21-
9.11) and 11.75 ms (90%CI 10.17-13.33) for women.
The overall estimate at Cmax was 9.56 ms (90%CI 8.49-
10.63).
No difference was found for Tpeak-Tend with
the 90%CI of both populations almost completely
overlapping (Figure 2): at Cmax men presented values of
4.62 ms (90%CI: 3.79; 5.46) whereas women presented
slightly higher values: 4.85 ms (90%CI: 3.95; 5.74). The
predictedTpeak-Tend values at the overall Cmax were
4.70 ms (90%CI: 4.08; 5.31).
The intercept and slope differences betweenmen and
women are shown in the Supplemental Table S4.
Levofloxacin
Levofloxacin elicited a smaller QTcF and J-
Tpeakc than moxifloxacin. The QTcF slope was
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Figure 2. Relationship between moxifloxacin and levofloxacin plasma concentrations andQTcF,J-TpeakcJ,andTpeak-Tend.Regression lines
with 2-sided 90% confidence regions are denoted by shaded areas. The means and whiskers show the predicted values for QTcF,J-TpeakcJ,
andTpeak-Tend at Cmax concentrations (the overall geometric mean of the individual Cmax values and the geometric means of the individual Cmax
values by sex). Cmax indicates peak concentration; Te, Tend; Tp, Tpeak.
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greater for men than for women (Table 2), which is
the opposite of what is seen after moxifloxacin admin-
istration. Figure 2 shows that the QTcF overlap
zone of the 90% confidence regions is wider at smaller
concentrations, indicating that sex-related differences in
QTcF seem to be more evident at higher concentra-
tions. The concentration-effect analysis shows that the
QTcF value at the overall Cmax was 9.40 ms (90%CI
8.21-10.59): 9.20 ms (90%CI 7.64-10.76) for men and
9.52 ms (90%CI 7.68-11.35) for women.
Almost consistently, men had slightly higher values
of J-TpeakcJ than women across the concentration
profile (Figure 2). Estimates for J-TpeakcJ at Cmax
were 4.17ms formen (90%CI 2.78-5.56) and 2.70ms for
women (90%CI 1.07-4.34). The overall estimate was of
3.54ms (90%CI 2.48-4.60). Again, this was the opposite
of the effect seen with moxifloxacin.
In contrast to the previous parameters, women had
greater Tpeak-Tend point estimates than men (Ta-
ble 2). At Cmax men presented estimates of 2.87 ms
(90%CI 1.99-3.74), and women presented values of
5.52 ms (90%CI 4.51-6.53). TheTpeak-Tend value at
the overall Cmax was 4.03 ms (90%CI 3.36-4.69). Slope
and intercept differences between men and women are
shown in Supplemental Table S4.
Discussion
The literature indicates that of all the available fluoro-
quinolones, moxifloxacin carries the greatest risk of QT
prolongation. As a result, it is advised that it should be
used in caution in patients with predisposing factors for
TdP.28,29
Women generally have a longer QTc than men30 and
an increased risk of drug-induced TdP.31 These sex
differences seem to be multifactorial and are still not
very well understood.32–35 Testosterone was reported
to shorten the action potential duration in guinea pigs
by decreasing the inward-depolarizing L-type calcium
current (ICa-L) and increasing the outward-repolarizing
“slow” delayed rectifier potassium current (IKs).35 In
healthy adult subjects the shorter QTc in men than
in women was related to a shorter J-Tpeak interval, a
difference that diminishedwith age. The influence of sex
hormones is also supported by findings showing similar
QTc intervals at birth in male and female subjects.36
The early repolarization changes in men were shown
to be influenced more by the effect of testosterone on
calcium currents than its effects on IKs.5 Testosterone
also diminished the proarrhythmic effects of the pure
hERG blocker dofetilide in female rabbits.30 Jonsson
et al4 have found that both IKs and IKr are influenced
by sex hormones whereby estrogen reduces IKs and
IKr expression, whereas progesterone enhances IKs.
Testosterone, by contrast, enhances both IKr and IKs.
This suggests that sex differences must be considered
in thorough QT studies and that hormonal cycles may
impact their results.The actions of sex hormones on
cardiac ion channels are likely to contribute to the
sex differences in cardiac repolarization processes and
susceptibility of TdP.
In this study the assessment of ECG subintervals
showed clear sex differences with moxifloxacin and
levofloxacin. The QTcF prolongation of moxifloxacin
in women was due to a prolongation of J-TpeakcJ of
approximately 12 ms and a prolongation of Tpeak-Tend
of approximately 5 ms. Men registered smaller values
of J-TpeakcJ (8 ms) and similar time-course values of
Tpeak-Tend (5 ms) when compared with women. This
suggests that the greater effect in women on QTcF is
due to their greater increase of J-TpeakcJ. Our results are
well aligned with the previous work from Matsukura
et al. In their study, women were also shown to be
more sensitive than men to the moxifloxacin-induced
J-Tpeak prolongation and QTcF, whereas Tpeak-Tend
values were similar between the sex groups21. In women
levofloxacin prolonged Tpeak-Tend by 6ms and J-TpeakcJ
by 3 ms. Men presented higher J-TpeakcJ values and
smaller Tpeak-Tend values. With moxifloxacin, women
demonstrated greater increase in QTcF and J-Tpeak,
whereas with levofloxacin, they demonstrated a greater
increase in Tpeak-Tend.
In summary, moxifloxacin showed a greater effect
in women on the J-TpeakcJ interval, which accounted
for most of their prolongation of QTcF. Levofloxacin
showed a different pattern of effect as women had less
effect on J-TpeakcJ, a more pronounced effect on Tpeak-
Tend, and the net effect on QTcF was a smaller effect in
women.
The prolongation of J-Tpeak seen for moxifloxacin
and levofloxacin is in agreement with electrophysiology
studies and indicates that drug-induced changes in T-
wave morphology are directly related to the amount
of hERG potassium channel block. Moxifloxacin was
shown to be a more potent prolonger of QTcF and had
a pronounced effect on J-Tpeakc, consistent with its ef-
fects on both IKr and IKs channels, whereas levofloxacin
had small and short-lived effect on J-Tpeakc. Patch-
clamp analyses suggested a roughly equipotent binding
of moxifloxacin to IKr and IKs potassium channels.1,14
In contrast, levofloxacin has been shown to have effects
on IKr channels only at relatively high concentrations,
and IKs was not a target for block by levofloxacin
because high concentrations produced only modest
reductions in IKs.18
In this study moxifloxacin and levofloxacin pre-
sented inverse sex-specific effects. The increase of early
repolarization duration in women, measured as the
heart rate corrected J-Tpeak interval (where ICa-L, IKr,
and late sodium current play a major role) was less
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pronounced with levofloxacin than with moxifloxacin.
Therefore, women seem to be more sensitive to a dual
block, in this case to moxifloxacin, a recognized IKs
and IKr inhibitor. In principle, considering that a larger
prolonging effect of the J-Tpeak interval may result in a
greater risk of TdP, our data would suggest that thera-
peutic doses of moxifloxacin have a considerable higher
risk of TdP in women than supratherapeutic doses of
levofloxacin. These findings suggest that sex hormone–
dependent differences in IKs may be involved in these
apparent differences in QT subintervals between moxi-
floxacin and levofloxacin. Our results provide valuable
insights into possible sex differences, the importance
of female enrollment in cardiac assessments, and con-
tribute to the estimated proarrhythmic potential of new
chemical entities.
Limitations
This was a retrospective analysis, and the studies were
not designed to explore the effects of moxifloxacin and
levofloxacin on the QTc subintervals and the respective
sex differences. However, the sample size utilized and
the statistical analyses are sufficiently robust, and the
results align well with previous published work by our
research group and others.
In addition to the above outlined hormone effects,
progesterone was shown to shorten action potential
duration in guinea pigs mostly through inhibition of
inward ICa and enhancement of IKs.37 In women pro-
gesterone fluctuates through the menstrual cycle, and
estrogen seems to have an opposing effect on cardiac
repolarization.38,39 This study does not explore the indi-
vidual contributions of sex hormones and their effects
in combination with moxifloxacin or levofloxacin on T-
wave morphology.
The study did not record menstrual cycles and did
not measure sex hormones. More studies considering
hormonal fluctuations would be desirable.
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